34. UTILIZATION PATTERNS OF COLISTIN AND ASSOCIATED NEPHROTOXICITY IN PATIENTS WITH KLEBSIELLA PNEUMONIAE INFECTIONS AT THONG NHAT HOSPITAL
Main Article Content
Abstract
Objective: To investigate the characteristics of colistin use and nephrotoxicity in patients with Klebsiella pneumoniae infections at Thong Nhat Hospital. Subject and method: This cross-sectional descriptive study was conducted on medical records of patients diagnosed with Klebsiella pneumoniae infections treated with colistin from January to June 2023 at Thong Nhat Hospital. Results: There were 54 medical records of patients infected with Klebsiella pneumoniae who were prescribed colistin and met the research criteria. The sensitivity of Klebsiella pneumoniae to various antibiotic groups was below 50%, except for a sensitivity of 73.0% to colistin and 63.6% to amikacin. All patients received colistin in combination regimens: dual (34.3%), triple (58.6%), and quadruple (7.1%), most commonly with carbapenem and an antibiotic active against Methicillin-resistant Staphylococcus aureus. A loading dose of colistin was administered to 47.2% of patients, with an average loading dose of 8.7 ± 1.1 million international units (MIU). The median maintenance daily dose was 6.8 MIU (interquartile range [IQR] 6.0-9.0), and the total cumulative dose was 45.0 MIU (IQR 27.0-65.3). Among the 43 cases evaluated for acute nephrotoxicity, 21 patients developed acute kidney injury, with 33.3% at risk, 23.8% injured, and 42.9% in failure according to the RIFLE criteria, with a median onset time of nephrotoxicity at 5.0 days (IQR 4.0-5.0). Conclusion: The incidence of acute kidney injury during colistin treatment for Klebsiella pneumoniae infections is high. Enhancing the closely monitoring renal function during treatment is crucial.
Article Details
Keywords
Klebsiella pneumoniae, antibiotic resistance, colistin, acute kidney injury
References
[2] Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005;40(9):1333-41.
[3] Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney international. 2008;73(5):538-46.
[4] Nguyễn Bích Tuyền, Đỗ Thị Phương Dung, Bùi Thị Hương Quỳnh, Võ Duy Thông. Phân tích việc sử dụng colistin tại bệnh viện Đa khoa Đồng Nai. Tạp chí Y học Việt Nam. 2021;500(2):118-24.
[5] Phạm Thị Mỹ Hoa, Phạm Hồng Thắm, Trương Thị Hà, Đinh Hữu Hào, Huỳnh Văn Ân, Trần Mạnh Hùng. Khảo sát tình hình sử dụng colistin từ tháng 01 đến tháng 06 năm 2020 tại bệnh viện Nhân dân Gia Định. Tạp chí Y học TP HCM. 2021;25(4):179-86.
[6] Nguyễn Thị Uyên, Phạm Đình Thắng, Phạm Thị Thu Hiền, Bùi Thị Hương Quỳnh. Tỷ lệ nhiễm và đề kháng kháng sinh của Klebsiella pneumoniae phân lập tại bệnh viện Thống Nhất giai đoạn 2018-2022. Tạp chí Y học Cộng đồng. 2023;64(8):60-7.
[7] Võ Quang Huy, Lê Thị Thu Ngân, Võ Thị Hà, Nguyễn Minh Hà. Tình hình đề kháng kháng sinh của Klebsiella pneumoniae tại Bệnh viện Nguyễn Tri Phương giai đoạn 2019-2022. Tạp chí Y học Việt Nam. 2023;527(2):163-7.
[8] Nguyễn Bảo Kim, Nguyễn Trung Nghĩa, Nguyễn Thị Hà, Bùi Sơn Nhật. Khảo sát thực trạng sử dụng colistin tại bệnh viện E. Tạp chí Y học Việt Nam. 2023;528(1):368-72.
[9] Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39.
[10] Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M. Molecular Mechanisms of Colistin-Induced Nephrotoxicity. Molecules (Basel, Switzerland). 2019;24(3).